← Back to Clinical Trials
Recruiting NCT05794087

NCT05794087 The Role of Macrophage Activation in Lung Injury Following Ozone Exposure

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05794087
Status Recruiting
Phase
Sponsor Rutgers, The State University of New Jersey
Condition Air Pollution
Study Type INTERVENTIONAL
Enrollment 120 participants
Start Date 2023-02-07
Primary Completion 2027-06-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 40 Years
Study Type INTERVENTIONAL
Interventions
Clean AirOzone

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 120 participants in total. It began in 2023-02-07 with a primary completion date of 2027-06-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of the study is to better understand the mechanisms of lung injury from ozone exposure. Subjects will participate in two exposure sessions: filtered air and 0.2 ppm ozone. The exposure visits will be at least 2 weeks apart. Subjects will be asked to produce sputum through coughing after each exposure. The samples will be analyzed for macrophage activity.

Eligibility Criteria

Exclusion Criteria: * Cardiovascular disease * Respiratory disease * Recent (within 4 weeks) respiratory or COVID-19 symptoms * Diabetes * Pregnancy * HIV Infection * History of smoking within the past 5 years. * Orthopedic or rheumatologic conditions which would interfere with cycle use * Inability to produce a sputum plug at screening * Daily use of antioxidant supplements, excluding those in a multivitamin. These supplements include Vitamin C or E, selenium, beta-carotene, lycopene, lutein, zeaxanthin and ginkgo biloba. Supplements taken less frequently but at least once a week will be reviewed by the principal investigator for eligibility determination.

Contact & Investigator

Central Contact

Kathleen Black, PhD

✉ kgblack@eohsi.rutgers.edu

📞 8484456049

Principal Investigator

Howard M Kipen, MD

PRINCIPAL INVESTIGATOR

Rutgers School of Public Health

Frequently Asked Questions

Who can join the NCT05794087 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 40 Years, studying Air Pollution. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05794087 currently recruiting?

Yes, NCT05794087 is actively recruiting participants. Contact the research team at kgblack@eohsi.rutgers.edu for enrollment information.

Where is the NCT05794087 trial being conducted?

This trial is being conducted at Piscataway, United States.

Who is sponsoring the NCT05794087 clinical trial?

NCT05794087 is sponsored by Rutgers, The State University of New Jersey. The principal investigator is Howard M Kipen, MD at Rutgers School of Public Health. The trial plans to enroll 120 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology